Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Neulasta Market Growth Potential: How Will Market Size Change Through 2030?
The historic period’s growth was driven by factors including the broader use of chemotherapy, a higher occurrence of neutropenia caused by treatment, the availability of pegylated growth factors, expanded protocols for supportive oncology care, and the uptake of prefilled injection devices.
The expansion observed during the forecast period stems from rising need for user-friendly medication administration methods, greater financial commitments in biosimilar competition, broader uptake of oncology therapies administered at home, heightened emphasis on patient-focused cancer management, and increased utilization of extended-release biologic agents. Key developments shaping this period encompass growing utilization of neutropenia treatments with prolonged action, wider deployment of wearable injector devices, expansion of complementary cancer care, increased preference for cancer treatment in outpatient settings, and a stronger focus on therapy compliance.
Download A Free Sample Report For Comprehensive Market Insights:
Neulasta Market Growth Drivers: What Factors Are Accelerating Expansion?
The expansion of the neulasta market is being fueled by the growing frequency of cancer diagnoses. Cancer encompasses a range of conditions marked by uncontrolled cell proliferation, potentially invading other tissues. This rise in cancer cases is largely linked to an aging global population, as the probability of developing the disease grows with increased life expectancy. By preventing neutropenia brought on by chemotherapy, stimulating white blood cell count, and lowering infection susceptibility in patients receiving such therapy, neulasta, a treatment based on pegfilgrastim, plays a crucial role in cancer management. As an example, a report from the Australian Institute of Health and Welfare in August 2024, a national health statistics organization based in Australia, forecasts that new cancer cases in the country will reach about 209,000 by 2034, climbing from an estimated 169,000 in 2024. It also notes that cancer is predicted to be responsible for roughly three out of every ten deaths in 2024. Consequently, the increasing prevalence of cancer will propel the neulasta market.
Neulasta Market Driver: Personalized Medicine Drives Growth In The Market
The neulasta market’s advancement is anticipated to be spurred by the heightened use of personalized medicine. This approach customizes therapies to align with individual patient characteristics, boosting their effectiveness and decreasing adverse reactions. Factors such as progress in genomics and biotechnology, which allow for treatments that are more effective and have fewer side effects, along with a growing need for precision in handling intricate illnesses like cancer and uncommon genetic disorders, are driving the uptake of personalized medicine. Through accurate dosing and sophisticated administration methods like autoinjectors, neulasta (pegfilgrastim) effectively averts chemotherapy-associated neutropenia, customizing care to fit each patient’s specific requirements and chemotherapy schedule. According to the Personalized Medicine Coalition, a US nonprofit, in February 2024, the FDA—a US federal body under the Department of Health and Human Services—endorsed 16 novel personalized therapies for rare disease patients in 2023, a rise from just 6 in 2022. Among these 2023 approvals were seven cancer medications and three for other ailments. Thus, the rising trend of personalized medicine will drive the neulasta market.
Neulasta Market Segment Analysis: What Are The Major Market Categories?
The neulasta market covered in this report is segmented –
1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications
2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens
3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services
4) By End User Patients: Adult Patients, Pediatric Patients
Neulasta Market Trends: What Is Shaping Future Industry Growth?
A major trend within the neulasta market is the adoption of innovative drug delivery methods, particularly prefilled autoinjectors, which are being pursued as a strategy to secure a competitive advantage. These autoinjectors are preloaded self-injection devices that facilitate simple and convenient self-administration by patients. An illustration of this was seen in March 2023, when the FDA approved a prefilled, single-dose autoinjector version of Udenyca (pegfilgrastim-cbqv), a biosimilar to pegfilgrastim developed by Coherus Biosciences, a U.S.-based biopharmaceutical company. Designed to treat and prevent febrile neutropenia—a frequent side effect of chemotherapy—this device enables patients to administer pegfilgrastim on the day following chemotherapy, thereby lowering the likelihood of developing febrile neutropenia. Its mechanism relies on a push-on-skin activation feature that ensures reliable and instantaneous delivery of the full pegfilgrastim dose.
Neulasta Market Leading Companies Driving Competitive Growth
Major companies operating in the neulasta market are Amgen Inc.
Access The Complete Neulasta Market Report:
Neulasta Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the neulasta market in 2025. The regions covered in the neulasta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model